
## **Cancer and Fertility**

Joanne Frankel Kelvin, MSN, RN, AOCN
Clinical Nurse Specialist
Memorial Sloan-Kettering Cancer Center



## Advances in cancer treatment have led to improvements in survival

#### Survival rates

Adult cancers 68% Pediatric cancers 83%

## ~13.7 million cancer survivors in the US 5% are younger than 40 years of age

	0–9	10–19	20–29	30–39
Male	18,499	43,137	74,785	134,634
Female	8,636	36,912	105,114	250,921

Siegel 2012, De Moor 2013



### **Cancer treatments affect fertility**

### Surgery

If reproductive structures removed/altered

### Radiation Therapy

Based on field of treatment and dose

### Chemotherapy and Hormonal Therapy

Based on agent and dose







## Patient factors also affect fertility

- Age (females)
- Diagnosis
- Obesity
- Tobacco smoking, alcohol, drugs
- Pre-treatment fertility

## Fertility is an important issue for cancer survivors

### Many young cancer patients...


- Have not yet started or completed their families at the time of diagnosis
- Want to be parents after treatment
- Do not recall being told of risk of infertility
- Are distressed or concerned about possibility of infertility


Crawshaw, et al, 2009; Duffy, et al, 2005; Partridge, et al, 2004; Peate, et al, 2009; Schover, et al, 1999; Schover, et al, 2002; Schover, 2005; Schover, et al, 2002; Thewes, et al, 2005; Tschudin & Bitzer, 2009; Wenzel, et al, 2005


# Clinicians don't always discuss fertility with their patients

- Believe this is important
- Inadequate knowledge
- Barriers
  - Lack of time
  - Lack of resources
  - Concern about cost
  - Don't know where to refer

# There is national recognition of the need to address fertility concerns







## There is professional recognition of the need to address fertility concerns

### Health care providers have a responsibility to

- Inform patients about the risks that their cancer treatment will permanently impair fertility
- Discuss options for fertility preservation and parenting after cancer
- Refer to appropriate specialists

American Society of Clinical Oncology (Loren et al, 2013)

American Medical Association (2013)

NCCN AYA Adolescent and Young Adult Clinical Oncology Guidelines (NCCN, 2012)

European Society for Medical Oncology (Pentheroudakis et al, 2010)

American Academy of Pediatrics (Fallat et al, 2008)


American Society of Reproductive Medicine (ASRM, 2005)

### **Outline**


- Basics of reproductive biology
- Effects of treatment on fertility
- Options for fertility preservation
- Resources at MSKCC to help you discuss fertility with your patients


### **MALES**


## Basics of Reproductive Biology Effects of Treatment on Fertility Options for Fertility Preservation



## **Spermatogenesis and Ejaculation**







## **Fertility Effects of Treatment**

#### Impaired sperm production

Depletion of stem cells and developing sperm
 Recovery – Oligospermia – Azoospermia




#### Impaired sperm transport

Injury to pelvic ducts/blood vessels/nerves → erectile/ejaculatory dysfunction

### Pituitary gland dysfunction

Disruption of hypothalamicpituitary-gonadal axis



## **Evaluation of Male Fertility**

It is impossible to predict with certainty who will be affected permanently

Semen analysis (WHO criteria, 2010)

Volume
 1.5 (1.4–1.7) ml

Sperm concentration 15 (12–16) million/ml


Progressive motility 32 (31–34)%

• Vitality 58 (55–63)%

DNA integrity testing not included

- Hormonal analysis
  - FSH, LH, Testosterone

# Males Fertility Preservation Options



### John



### 19 year old male

- Diagnosis: Testicular cancer
- Treatment plan: Orchiectomy followed by chemotherapy with BEP (bleomycin, etoposide, cisplatin)
- Social: single college student, no children

What is available for this patient?


## **Sperm Cryopreservation (Banking)**

Semen collected, analyzed, placed in vials, frozen, and stored for possible future use

Sperm Bank Collection

Manual stimulation
3 collections
Abstain 2-5 days

Electroejaculation **EEJ** 




If patient is unable to collect manually

**Testicular Sperm Extraction TESE** 



If patient is azoospermic

### Peter



### 8 year old male

- Diagnosis: Rhabdomyosarcoma
- Treatment plan: Chemotherapy with VAC (vincristine, doxorubicin, cyclophosphamide)
- Social: school-aged child

What is available for this patient?

### **Testicular Tissue Cryopreservation**

- Tissue biopsied, frozen, and stored for potential future use
  - Tissue reimplantation no live births to date
     Concern about re-implanting cancer cells
  - In vitro maturation no live births to date
- Investigational

### Sam




### 38 year old male

- Diagnosis: Rectal cancer
- Treatment plan: Pelvic RT with CI fluorouracil followed by surgical resection and adjuvant chemotherapy with FOLFOX (fluorouracil and oxaliplatin)
- Social: married with 3 year old son

What is available for this patient?


## **Gonadal Shielding**

### During pelvic/inguinal field radiation




- With IMRT to minimize testicular dose
- Also recommend sperm banking before treatment

# Males Fertility Preservation Options




### **FEMALES**

## Basics of Reproductive Biology Effects of Treatment on Fertility Options for Fertility Preservation




### **Ovarian Cortex**



Ovarian Reserve = number and quality of eggs

### **Effect of Age on Ovarian Reserve**



**Loss of follicles** → **Infertility, Menopause** 

## Females Fertility Effects of Treatment

#### Depletion of ovarian follicle pool (oocytes)

▶ Premature ovarian failure → infertility, menopause May have narrowed window of reproductive opportunity

#### Pituitary gland dysfunction

Disruption of hypothalamic-pituitary-gonadal axis

#### **Uterine damage**

- Vascular changes, endometrial injury → inability to support embryo implantation
- Myometrial fibrosis → inability to accommodate a growing fetus




## **Evaluation of Female Fertility**

## It is impossible to predict with certainty who will be affected permanently

- Transvaginal ultrasound
  - Ovarian antral follicle count
- Hormonal analysis
  - Anti-Mullerian Hormone (AMH)
  - Follicle Stimulating Hormone (FSH)
  - Estradiol



# Females Fertility Preservation Options



### Susan




### 33 year old female

- Diagnosis: Breast cancer
- ► Treatment plan: Mastectomy with immediate reconstruction followed by AC-T (doxorubicin, cyclophosphamide, paclitaxel) → tamoxifen
- Social: married, 1 child

What is available for this patient?


### **Embryo Cryopreservation**

Ovarian Stimulation




Daily hormone injections
Starts day 2 of menses
Continues for ~10 days






## **Embryo Cryopreservation**









Cryopreservation



## Kelly



### 18 year old female

- Diagnosis: Relapsed Hodgkin Lymphoma
- Prior treatment: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) 2 years ago
- Treatment plan: BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
- Social: single college student, no children

What is available for this patient?

## **Oocyte Cryopreservation**





Cryopreservation




## **Embryo/Oocyte Cryopreservation**

- Concerns about delay in treatment
  - Generally requires about 3 weeks of time
  - Expedited referrals
  - Downregulation of pituitary with GnRHa
- ▶ Concerns about ↑ estrogen
  - No evidence about effect on recurrence/survival
  - Aromatase inhibitor (eg, letrozole) can lower estrogen levels

## **Embryo/Oocyte Cryopreservation**

- Concerns about specific medical risks
  - Bleeding if thrombocytopenic or liver dysfunction
  - Infection if neutropenic
  - History of DVT/VTE
  - Anesthesia complications because of disease in the chest

## **Embryo Transfer**



Success Rates with Thawed Embryos
From Non-Donor Oocytes

% Transfers Resulting in Live Births

<35	35-37	38-40	41-42
39.3%	35.7%	30.3%	24.5%

## Stephanie



#### 18 year old female

- Diagnosis: Non-Hodgkin Lymphoma
- Treatment plan: BEAM (BCNU, etoposide, cytarabine, melphalan), must start within 5 days
- Social: single college student, no children

What is available for this patient?

### **Ovarian Tissue Cryopreservation**

- Ovary resected, cortex dissected, frozen, and stored for potential future use
  - Tissue reimplantation ~20 live births to date
     Concern about re-implanting cancer cells
  - In vitro maturation no live births to date
- Investigational

### **Ovarian Suppression**

### GnRH agonist (leuprolide)

- To prevent recruitment of follicles, potentially protecting them from effects of chemotherapy
- Initiated 2-4 weeks before starting chemotherapy, continued monthly throughout treatment
- Investigational studied primarily in breast cancer and lymphoma with conflicting results

### **Barbara**



#### 3 year old female


- Diagnosis: Neuroblastoma
- Treatment plan: RT and multiagent chemotherapy
- Social: pre-school child

What is available for this patient?

### **Ovarian Tissue Cryopreservation**

- Ovary resected, cortex dissected, frozen, and stored for potential future use
  - Tissue reimplantation no live births to date
     Concern about re-implanting cancer cells
  - In vitro maturation no live births to date
- Investigational

### Ellen




### 28 year old female

- Diagnosis: Leiomyosarcoma of bladder
- Treatment plan: Pelvic RT with gemcitabine, followed by partial cystectomy
- Social: married, 2 year old daughter

What is available for this patient?

### **Ovarian Transposition**

### Prior to pelvic/inguinal field radiation




- With IMRT to minimize ovarian & uterine dose
- Also consider embryo/oocyte cryopreservation
- If IVF needed in the future patient will need transabdominal retrieval
- Does not protect the uterus

### **Alternative Treatment For Select Patients**

Early stage cervical cancer


Radical Trachelectomy

Rectal cancerNo pelvic radiation



Non-gonadotoxic chemotherapy regimen

# Females Fertility Preservation Options



## What does this mean for you?

Recognize that despite your personal assumptions about which patients may be interested in fertility preservation, the following factors may NOT be significant from the patient's perspective:

- Age
- Previous children
- Religious and ethical beliefs
- Advanced disease
- Limited financial resources

## What does this mean for you?

- Initiate the discussion in those at risk
  - Inform patient of risk of infertility
  - Assess interest in future parenting
  - Explain options for fertility preservation
- Refer patients interested in learning more or who want to pursue fertility preservation

The goal is to ensure patients have the opportunity to participate in the decision-making – to avoid regret in the future